Total
0
Shares
Mach7 Technologies (ASX:M7T) - CEO, Mike Lampron - The Market Herald
CEO, Mike Lampron
Source: Mach7 Technologies
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Mach7 Technologies (M7T) has secured a $7.9 million contract through its wholly-owned subsidiary with U.S. nonprofit Adventist Health System
  • Mach7 is set to roll out its full suite of picture archive communication system across 22 hospitals in the U.S., with the first round of orders expected this quarter
  • The $7.9 million arrangement includes migration services and five years of support and maintenance
  • Mach7 Chief Executive Officer Mike Lampron said he is delighted with the new collaborative partnership
  • Mach7 shares are trading 9.40 per cent higher at $1.46 each

Mach7 Technologies (M7T) has secured a $7.9 million contract through its wholly-owned subsidiary with U.S. nonprofit, Adventist Health System.

The contract amendment is for its license of the Mach7 PACS (Picture Archive Communication System), an integrated enterprise imaging solution designed to streamline hospital workflows.

The initial contract with Adventist in April 2020 included the provision of its eUnity Diagnostic Viewer and Mach7 Universal Worklist to one of the hospitals in the Adventist Health network.

Now, under the new contract, Mach7 will supply its full suite of PACS services across 22 hospitals in California, Hawaii and Oregon as part of the Adventist PACS replacement program.

The $7.9 million arrangement includes migration services and five years of support and maintenance.

According to the company, the software deployment will be implemented in stages as and when software licenses are ordered by individual hospitals in the Adventist Health group.

Mac7 expects the first round of orders for the quarter to represent roughly 7 per cent of the total contract value, as part of its longer-term goal to roll out Mach7 PACS across the majority of Adventist Health hospitals by the end of 2021.

Mach7 Chief Executive Officer Mike Lampron said he is delighted with the partnership.

"The collaborative partnership we have established with Adventist Health has allowed us to help them expand their enterprise imaging growth strategy," he explained.

"I am confident Mach7's full Enterprise PACS solution will provide a flexible
and scalable foundation that meets the needs of radiologists across their health
network," he added.

Mach7 shares are trading 9.40 per cent higher at $1.46 each at 12:01 pm AEDT.

M7T by the numbers
More From The Market Herald
Patrys (ASX:PAB) selects stable cell line for PAT-DX1 production

" AFT Pharmaceuticals (ASX:AFP) signs exclusive Maxigesic IV licensing agreement

AFT Pharmaceuticals has signed an exclusive Maxigesic IV licensing agreement for eight new European markets.
Althea Group (ASX:AGH) - CEO, Joshua Fegan - The Market Herald

" Althea Group’s (ASX:AGH) subsidiary gets A$137K order to make cannabis concentrates

Althea Group’s (AGH) subsidiary, Peak Processing Solutions, has received an C$134,000 (roughly A$137,216) purchase order from Peace Naturals Project.
Immutep (ASX:IMM) - CEO, Marc Voigt (left) - The Market Herald

" Immutep (ASX:IMM) expands TACTI-002 study

Immutep (IMM) has expanded Part B of its TACTI-002 phase two trial, following a recommendation from the data monitoring committee.
ImpediMed (ASX:IPD) - CEO, Rick Carreon - The Market Herald

" ImpediMed (ASX:IPD) completes 200,000 patient tests

ImpediMed  (IPD) says it has reached a milestone 200,000 patient tests for SOZO testing.